PCSK9 Inhibitors for Cholesterol Reduction

Many patients do not achieve target LDL goals, despite statin treatment. A new class of self-injected cholesterol drugs, the PCSK9 inhibitors, may address this gap. Clinical evidence shows that PCSK9 inhibition is as promising as statins as a target to treat CAD. In 2015, the FDA is expected to approve the first of these drugs.6

 


Continue Reading